- Conditions
- Dry Eye Syndromes
- Interventions
- Ecabet 2.83%, Ecabet 3.70%, Vehicle
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 3
- States / cities
- Lewiston, Maine • Andover, Massachusetts • Dover, New Hampshire
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 27
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- HER2 Low Breast Carcinoma, Triple Negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma
- Interventions
- ARX788, Computed Tomography (CT), Biospecimen Collection, Amiloride
- Drug · Procedure
- Lead sponsor
- Laura Huppert, MD, BA
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Diabetic Retinopathy, Low Vision
- Interventions
- Eye4, Placebo
- Device · Other
- Lead sponsor
- Eyedaptic
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Laguna Hills, California
- Conditions
- Dry Eye Syndrome
- Interventions
- Rebamipide 2% ophthalmic suspension, Placebo (vehicle)
- Drug
- Lead sponsor
- Kubota Vision Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Artesia, California + 31 more
- Conditions
- Dry Eye
- Interventions
- Ketorolac/HPMC, HPMC, Vehicle
- Drug
- Lead sponsor
- ORA, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Inflammation, Pain
- Interventions
- Vehicle of Loteprednol Etabonate, Loteprednol Etabonate
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Acute Bacterial Corneal Ulcers, Bacterial Keratitis
- Interventions
- Gatifloxacin 0.3% ophthalmic solution, Ciprofloxacin 0.3% ophthalmic solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Hodgkin Disease
- Interventions
- ABVE-PC, DECA
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ocular Inflammation
- Interventions
- Loteprednol Etabonate, Vehicle of Ophthalmic Loteprednol Etabonate
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- High Point, North Carolina
- Conditions
- Hyperemia
- Interventions
- Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 507 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Havre de Grace, Maryland • Andover, Massachusetts + 1 more
- Conditions
- Open Angle Glaucoma
- Interventions
- Acular LS, Pred Forte, Refresh Tears
- Drug · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Glioblastoma Multiforme
- Interventions
- Steroid eye drops, Vasoconstrictor eye drops, Cold compress, Ophthalmic steroid ointment, Depatuxizumab mafodotin, Temozolomide, Radiation
- Drug · Other · Radiation
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Tampa, Florida • Chicago, Illinois + 6 more
- Conditions
- Hyperemia
- Interventions
- Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Ocular Redness
- Interventions
- Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation, Lumify® (brimonidine tartrate ophthalmic solution 0.025%)
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 6
- States / cities
- Colorado Springs, Colorado • Louisville, Kentucky • Andover, Massachusetts + 3 more
- Conditions
- Adenoviral Conjunctivitis
- Interventions
- SHP640, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- Not listed
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 29
- States / cities
- Glendale, California • Los Angeles, California • Torrance, California + 25 more
- Conditions
- Endogenous Anterior Uveitis
- Interventions
- Difluprednate 0.05% ophthalmic emulsion, Prednisolone acetate 1.0% ophthalmic suspension
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Dry Eye Disease
- Interventions
- FID123300 ocular lubricant
- Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 9
- States / cities
- Maitland, Florida • Orlando, Florida • Franklin Park, Illinois + 6 more
- Conditions
- Dry Eye
- Interventions
- SYSTANE Ultra, Optive
- Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Dry Eye Syndromes
- Interventions
- High concentration SI-614, Low concentration SI-614, Vehicle
- Drug
- Lead sponsor
- Seikagaku Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Dry Eye
- Interventions
- Cyclosporin 0.05% emulsion, Endura, Refresh artificial tears
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Allergic Conjunctivitis
- Interventions
- ST266, Saline (0.9% NaCl)
- Biological · Drug
- Lead sponsor
- Noveome Biotherapeutics, formerly Stemnion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Andover, Massachusetts • Memphis, Tennessee
- Conditions
- Keratoconus
- Interventions
- Dextenza 0.4Mg Ophthalmic Insert, topical prednisolone acetate 1% (PredForte) eye drops
- Drug
- Lead sponsor
- Maanasa Indaram, MD
- Other
- Eligibility
- 13 Years to 64 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- San Francisco, California
- Conditions
- Glaucoma
- Interventions
- Prednisolone 1%, Ketorolac, Artificial Tears
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 2
- States / cities
- Miami, Florida • Pittsburgh, Pennsylvania
- Conditions
- Dry Eye Syndromes
- Interventions
- SJP-0035 0.001%, Placebo
- Drug
- Lead sponsor
- Senju Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 23
- States / cities
- Chandler, Arizona • Sun City, Arizona • Long Beach, California + 20 more